Safety and tolerability of injectable Rilpivirine LA in HPTN 076: A phase 2 HIV pre-exposure prophylaxis study in women

BACKGROUND: Daily oral TDF/FTC is protective against HIV infection when used for pre-exposure prophylaxis (PrEP). However, daily adherence to oral PrEP is difficult for many; therefore, finding alternative PrEP strategies remains a priority. HPTN 076 evaluated the long-acting injectable form of rilp...

Descripción completa

Detalles Bibliográficos
Autores principales: Bekker, L.G., Li, S., Pathak, S., Tolley, E.E., Marzinke, M.A., Justman, J.E., Mgodi, N.M., Chirenje, M., Swaminathan, S., Adeyeye, A., Farrior, J., Hendrix, C.W., Piwowar-Manning, E., Richardson, P., Eshelman, S.H., Redinger, H., Williams, P., Sista, N.D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Research paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7139112/
https://www.ncbi.nlm.nih.gov/pubmed/32280940
http://dx.doi.org/10.1016/j.eclinm.2020.100303

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7139112/
https://www.ncbi.nlm.nih.gov/pubmed/32280940
http://dx.doi.org/10.1016/j.eclinm.2020.100303

Ejemplares similares